The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1146 articles
The U.S. Food and Drug Administration (FDA) has announced a significant proposal to restrict the compounding of popular GLP-1 medications, including semaglutide and tirzepatide. This move aims to enhance patient safety and uphold the integrity of approved drug products. Here's a comprehensive look at what this means for individuals managing weight and diabetes.
The rise of GLP-1 medications like Ozempic and Mounjaro has brought about new conversations around their side effects, including the emerging concern of 'Ozempic breath.' This article delves into the causes, implications, and effective management strategies for this common issue.
Eli Lilly's groundbreaking oral GLP-1, Foundayo, is demonstrating a promising launch, exceeding initial expectations and hinting at a significant expansion of the weight loss and diabetes management market. Discover the latest insights and what it means for patients and the industry.
The rise of GLP-1 medications like Ozempic and Wegovy is transforming health and lifestyles, but it's also leading to an unexpected side effect: 'Ozempic breath'. This phenomenon is creating a surprising boon for confectionary companies, particularly Hershey, as consumers seek relief. Learn more about this fascinating intersection of pharmaceuticals and consumer goods.
The rise of GLP-1 medications like Ozempic and Mounjaro has coincided with a notable shift in aesthetic preferences, particularly concerning breast size. This article delves into the potential links, societal pressures, and practical considerations for women navigating these changes.
New research from the University of St Andrews offers a glimmer of hope for individuals using GLP-1 medications who become pregnant. This comprehensive review of nearly 50,000 pregnancies suggests a potentially lower risk of adverse outcomes than previously feared, though experts emphasize caution.
Eli Lilly's first quarter of 2026 saw record-breaking performance, largely propelled by the immense demand for its GLP-1 based therapies, Mounjaro and Zepbound. The pharmaceutical giant not only surpassed financial expectations but also significantly raised its full-year outlook, signaling continued growth and innovation in the metabolic disease space.
A new daily pill, Orforglipron, is emerging as a significant contender in the weight loss and diabetes management space, offering a potential oral alternative to injectable GLP-1 medications. This article delves into its mechanisms, trial results, and what it means for the future of treatment.
Losing weight with GLP-1 medications like semaglutide and tirzepatide is a significant achievement, but maintaining that loss after stopping treatment presents a major challenge. A new experimental procedure, duodenal mucosal resurfacing (DMR), is showing remarkable potential in helping individuals keep the pounds off.
